PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
0.870
-0.024 (-2.70%)
At close: Dec 5, 2025, 4:00 PM EST
0.850
-0.020 (-2.30%)
After-hours: Dec 5, 2025, 4:56 PM EST
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,453,539
Market Cap
47.61M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PDSB News
- 3 days ago - PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) - GlobeNewsWire
- 22 days ago - PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 24 days ago - PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering - GlobeNewsWire
- 25 days ago - PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 - GlobeNewsWire
- 4 weeks ago - PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 5 weeks ago - PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer - GlobeNewsWire